UBS analyst John Sourbeer initiated coverage of Akoya Biosciences with a Buy rating and $14 price target. The firm’s proprietary analysis, surveys and expert calls suggest above consensus revenue growth over the near and long- term, the analyst tells investors in a research note. UBS sees continued share gains with the Fusion, leading to improved consumable mix and eventual profitability.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AKYA:
- Akoya Biosciences to present results from spatial multiomics study
- Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting
- Akoya Biosciences participates in a conference call with JPMorgan
- Akoya Biosciences management to meet with Stephens
- Akoya reports preliminary Q4 revenue $20.7M-$21.2M, consensus $20.07M
